

Health Innovation Quarterly Update

31 March 2024



This document is solely for the use of professional investors and should not be relied upon by any other person. It is not intended for use by retail clients.

Important Information and Risk Factors

Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited is authorised and regulated by the Financial Conduct Authority.

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 and Type 2 licence from the Securities & Futures Commission of Hong Kong to market and distribute Baillie Gifford's range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong, Telephone +852 3756 5700.

Baillie Gifford Investment Management (Europe) Limited provides investment management and advisory services to European (excluding UK) clients. It was incorporated in Ireland in May 2018. Baillie Gifford Investment Management (Europe) Limited is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. Baillie Gifford Investment Management (Europe) Limited is also authorised in accordance with Regulation 7 of the AIFM Regulations, to provide management of portfolios of investments, including Individual Portfolio Management ('IPM') and Non-Core Services. Baillie Gifford Investment Management (Europe) Limited has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc.

Through passporting it has established Baillie Gifford Investment Management (Europe) Limited (Frankfurt Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in Germany. Similarly, it has established Baillie Gifford Investment Management (Europe) Limited (Amsterdam Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in The Netherlands.

Baillie Gifford Investment Management (Europe) Limited also has a representative office in Zurich, Switzerland pursuant to Art. 58 of the Federal Act on Financial Institutions ("FinIA"). The representative office is authorised by the Swiss Financial Market Supervisory Authority (FINMA). The representative office does not constitute a branch and therefore does not

**Calton Square, 1 Greenside Row, Edinburgh EH1 3AN
Telephone +44 (0)131 275 2000 bailliegifford.com**

have authority to commit Baillie Gifford Investment Management (Europe) Limited.

Baillie Gifford Investment Management (Europe) Limited is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited and Baillie Gifford & Co are authorised and regulated in the UK by the Financial Conduct Authority.

Persons resident or domiciled outwith the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

This document contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is based on a representative portfolio, new client portfolios may not mirror the representative portfolio exactly. As at March 31, 2024, in US dollars and sourced from Baillie Gifford & Co unless otherwise stated.

South Africa

Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

North America

Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission ('OSC'). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited ('BGE') relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.

Japan

Mitsubishi UFJ Baillie Gifford Asset Management Limited ('MUBGAM') is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited. MUBGAM is authorised and regulated by the Financial Conduct Authority.

South Korea

Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-Discretionary Investment Adviser.

Australia

Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This material is provided to you on the basis that you are a "wholesale client" within the meaning of section 761G of the Corporations Act 2001 (Cth) ("Corporations Act"). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this document be made available to a "retail client" within the meaning of section 761G of the Corporations Act. This material contains general information only. It does not take into account any person's objectives, financial situation or needs.

Israel

Baillie Gifford Overseas is not licensed under Israel's Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755-1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This document is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

Past Performance

Past performance is not a guide to future returns. Changes in investment strategies, contributions or withdrawals may materially alter the performance and results of the portfolio. Material market or economic conditions will have an impact on investment results. The returns presented in this document are gross of fees unless otherwise stated and reflect the reinvestment of dividends and interest.

Historical performance results for investment indexes and/or categories, generally do not reflect the deduction of transaction costs and/or custodial charges or the deduction of an investment management fee, the incurrence of which would have the effect of decreasing historical performance results. It should not be assumed that recommendations/ transactions made in the future will be profitable or will equal performance of the securities mentioned.

Potential for Profit and Loss

All investment strategies have the potential for profit and loss.

Stock Examples

Any stock examples, or images, used in this paper are not intended to represent recommendations to buy or sell, neither is it implied that they will prove profitable in the future. It is not known whether they will feature in any future portfolio produced by us. Any individual examples will represent only a small part of the overall portfolio and are inserted purely to help illustrate our investment style. A full list of portfolio holdings is available on request.

The commentary relates to the above mentioned strategy and not all stocks mentioned may be held in the portfolio.

Financial Intermediaries

This document is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

Product Overview

The strategy aims to produce capital growth over the long term. The investment policy is to invest mainly in global equities selected from companies involved in the healthcare industry and which are innovative in their focus. The strategy will not be restricted to equity securities in the healthcare sector as defined by any particular index. Investment will be concentrated by the number of stocks held but diversified across a range of healthcare themes.

Risk Analysis

Key Statistics


Number of Holdings	37
Typical Number of Holdings	25-50
Active Share	100%*
Rolling One Year Turnover	9%

*Relative to MSCI ACWI Index. Source: Baillie Gifford & Co, MSCI.

The extreme headwinds faced by innovative healthcare companies continue to abate

Turnover has ticked up as we seek to capitalise on recent market dislocations

Accelerating innovation and attractive valuations are providing plentiful opportunity



Baillie Gifford Key Facts

Assets under management and advice	US\$290.9bn
Number of clients	655
Number of employees	1817
Number of investment professionals	393

'Healing is a matter of time, but it is also a matter of opportunity'. Hippocrates

As the spectre of rapidly rising rates that has weighed so heavily on long-duration equities over recent years continues to lift, we are increasingly witnessing signs of healing within the innovative healthcare space. This is providing significant opportunities to us as long-term investors.

For example, we are seeing an acceleration in biological innovation, evidenced by a strong rise in new drug approvals in 2023, with the US Food and Drug Administration approving nearly 50% more new drugs than in 2022, and a revival in the number of clinical trials initiated.

Furthermore, as macroeconomic headwinds abate, there are positive indications that the funding environment for healthcare companies is recovering. This is particularly important for the healthcare ecosystem as it enables companies to progress clinical trials, invest in their pipelines, and further their research and development. Biopharmaceutical initial public offerings (IPOs) are already up 105% (annualised) in 2024 versus last year, and the capital raised so far in 2024 by the sector is almost 50% higher than the same period in 2023. The pace of equity follow-ons has also recovered meaningfully, with levels now back at pre-pandemic levels. Within our own portfolio too, we have seen a number of holdings take advantage of the improved backdrop to raise capital in the first quarter to fund their pipelines, including Denali, Alector, Sartorius and Sana. This will enable them to capitalise on the innovative treatments and technologies that they are developing.

Antifragile: things that gain from disorder. Nassim Taleb

Nassim Taleb's concept of anti-fragility resonates strongly with our own experience of investing in innovative healthcare companies. Antifragile refers to how certain entities can thrive amidst disorder, with the investment implication being that those companies that can weather adversity emerge stronger.

2022 and 2023 were undoubtedly two years of significant disorder for healthcare companies. Last year alone, the healthcare sector underperformed the broader global equity market by 20 per cent and our own portfolio also experienced a sharp drawdown in returns.

However, we believe that this disorder is now masking a large bifurcation between companies that

have succumbed to the disorder, and those that have used it to cement their competitive advantages and strengthen their resiliency.

Within the portfolio, as we look to the year ahead, there are a number of holdings which have not only emerged in a stronger position but have sizable catalysts for growth over the months ahead.

For example, 2023 was an excellent year for Dexcom, the continuous glucose monitoring (CGM) company, where it expanded its patient population to 2.3 million, launched its next-generation G7 device, and sold the Dexcom ONE in multiple new markets. In 2024, Dexcom has already gained approval from the FDA for Stelo, its over-the-counter CGM for those who do not need insulin therapy. This clearance is an important step that will materially expand its addressable market to encompass the 25 million people in the US living with type 2 diabetes.

Elsewhere, Vir has used its healthy cash balance to bolster its pipeline and stimulate further value creation for patients and investors. Vir is an immunology company with a focus on infectious diseases. It has already successfully proven the capabilities of its technology platform with its antibody-based treatment being administered to millions of patients during the pandemic. But it is also working on some of the major unmet needs in infectious diseases, including, Hepatitis, HIV, and RSV. This year, it has important readouts from its Hepatitis D and Hepatitis B programmes. As it progresses these trials, Vir has proactively reached out to our Health Systems Specialist, Maria Souza, to "find intelligence and connect us to the right people" to support its Hepatitis D market-shaping plan. Our intention is that it can benefit from our "connective tissue" within the healthcare ecosystem, which links entrepreneurs, investors, scientists, healthcare professionals and NGOs to improve our portfolio holdings' chances of success.

We are also expecting key readouts for Moderna in 2024, which will further prove the company's capabilities beyond its COVID-19 vaccine. We expect news on the approval of its RSV vaccine in the first half of the year, and multiple Phase 3 readouts later in 2024, including for its CMV, and combination flu and covid vaccines.

Ongoing monitoring and patience

Some companies will likely require ongoing patience and additional scrutiny. For example, WuXi Biologics, the Chinese contract research and development organisation, has recently been caught in the crosshairs of geopolitical tensions between the US and China. Several US

lawmakers are trying to advance a bill that will restrict WuXi's activities in the US. However, historically bills like this have had a low chance of being signed into law and we believe that the bear case scenario is now reflected in WuXi's stock price. Despite these concerns, the company continues to execute well and is investing in its overseas facilities to diversify its footprint. The bill's potential impact will take time to become evident and we will continue to monitor the situation closely.

We also believe that Alnylam, the gene-silencing pioneer, merits additional patience. It recently announced changes to its pivotal HELIOS-B trial, lengthening the trial by three months and splitting the patient population. Changes to clinical trials at this late stage are unusual and the market reacted badly to the news. However, the management team believe these changes will better highlight the superior efficacy of its drug. We await the results announcement in June and while this trial is important for Alnylam, it is just one in a broad and potentially lucrative pipeline for the company.

Exploiting market disorder

We can characterise the market of the past two years as one which has rewarded execution and punished missteps with the same vigour. As we enter an environment that is driven more by stock selection than market sentiment, it is creating interesting opportunities for us as long-term, fundamental-driven stock pickers. This has been evidenced by an uptick in transaction activity over the past quarter, as the team have taken advantage of valuation disconnects to purchase a number of new names for the portfolio.

For example, this quarter we initiated positions in BioNTech and Twist, both of which have fallen by around 70% from their peaks. BioNTech is most known for its COVID-19 vaccine, however, it has used the substantial cash generated from that to progress its oncology pipeline, and now has one of the broadest and deepest pipelines in this area, that spans multiple technology modalities, a necessity in tackling the complexity and heterogeneity of cancers. Twist, on the other hand, is one of the core companies at the centre of the synthetic biology movement - the practice of programming biological systems to create therapies, diagnostics, energy, and materials. The DNA "writing" market is at a much earlier stage than the DNA sequencing market, but Twist has built an enviable position as the provider of choice, and we believe it has an exceptional growth trajectory ahead.

The recent success of the new generation of anti-obesity drugs has caused significant share price weakness in a number of medical companies treating

adjacent areas, as the market seems to have oversimplified the relationship between weight and chronic disease. This was the case with Inspire Medical and Insulet, which develop devices for sleep apnoea and diabetes delivery respectively. The market's preoccupation with GLP-1s caused the share prices of both companies to decline by almost 30%, providing an attractive entry point to two companies which we have long admired.

We have not, however, been complacent that all companies will display the requisite degree of anti-fragility that we require within the Health Innovation portfolio. A combination of management missteps and an inability to navigate the changing economic environment, has meant that Masimo, Teladoc, and Novocure have emerged as less resilient businesses and we have therefore taken the decision to sell them from the portfolio.

Outlook

Innovation across healthcare continues to advance strongly. Whether it be the increase in drug developer Research and development (R&D) budgets, new drugs approved, or clinical trial starts, these metrics demonstrate the health of the industry and provide a strong backdrop for its long-term prospects. Advancing technologies continue to bring a more data-driven era of personalised medicine closer. In the short term, industry revenues and profits are finally picking back up, improving market confidence, and resetting growth expectations higher.

We believe recent market uncertainty continues to mask the true potential of the companies in the portfolio. Valuations are extremely supportive, with the portfolio now trading at the lowest price to sales, and near the lowest price to earnings since its inception in 2018. This is despite the continued strong fundamentals of our holdings, which are growing their revenues and earnings at a rate that is at least double that of the index, while still investing for their futures, and therefore increasing their chances of long-term success.

As the companies' drug pipelines continue to advance, and their devices and services evidence a differentiated value proposition to patients and customers, we believe that they are well placed to emerge from the recent market disorder in robust health and full of opportunity.

Performance Objective

To outperform any sensible global index (default MSCI ACWI) by +3% gross of fees annualised, over a five year investment horizon.. The performance objective is aspirational and is not guaranteed. We don't use it to compile the portfolio and returns will vary. A single performance objective may not be appropriate across all vehicles and jurisdictions. We may not meet our investment objectives if, for example, our growth investment style is out of favour, or we misjudge the long-term earnings growth of our holdings.

Periodic Performance

GBP	Composite Net (%)	Benchmark (%)	Difference (%)
3 Months	2.8	9.3	-6.5
1 Year	-13.2	21.2	-34.4
3 Year	-14.5	10.7	-25.2
5 Year	2.3	12.1	-9.9
Since Inception	4.2	12.0	-7.7
USD	Composite Net (%)	Benchmark (%)	Difference (%)
3 Months	1.8	8.3	-6.5
1 Year	-11.3	23.8	-35.1
3 Year	-17.0	7.5	-24.4
5 Year	1.6	11.5	-9.8
Since Inception	4.0	11.7	-7.7
EUR	Composite Net (%)	Benchmark (%)	Difference (%)
3 Months	4.2	10.8	-6.6
1 Year	-10.8	24.5	-35.3
3 Year	-14.6	10.5	-25.1
5 Year	2.4	12.3	-9.9
Since Inception	5.0	12.7	-7.8
CAD	Composite Net (%)	Benchmark (%)	Difference (%)
3 Months	4.5	11.2	-6.7
1 Year	-11.3	23.8	-35.1
3 Year	-14.9	10.1	-25.1
5 Year	1.9	11.7	-9.8
Since Inception	4.6	12.4	-7.7
AUD	Composite Net (%)	Benchmark (%)	Difference (%)
3 Months	6.5	13.3	-6.8
1 Year	-9.0	27.1	-36.1
3 Year	-12.6	13.2	-25.7
5 Year	3.4	13.4	-10.0
Since Inception	5.6	13.5	-7.8

Annualised periods ended 31 March 2024. 3 Month & 1 Year figures are not annualised.

Inception date: 31 October 2018

Figures may not sum due to rounding.

Benchmark is MSCI ACWI Index.

Source: Revolution, MSCI.

The Health Innovation composite is more concentrated than the MSCI ACWI Index.

Discrete Performance

GBP	31/03/19- 31/03/20	31/03/20- 31/03/21	31/03/21- 31/03/22	31/03/22- 31/03/23	31/03/23- 31/03/24
Composite Net (%)	9.3	63.8	-21.4	-8.4	-13.2
Benchmark (%)	-6.2	39.6	12.9	-0.9	21.2
USD	31/03/19- 31/03/20	31/03/20- 31/03/21	31/03/21- 31/03/22	31/03/22- 31/03/23	31/03/23- 31/03/24
Composite Net (%)	4.0	82.3	-25.0	-14.0	-11.3
Benchmark (%)	-10.8	55.3	7.7	-7.0	23.8
EUR	31/03/19- 31/03/20	31/03/20- 31/03/21	31/03/21- 31/03/22	31/03/22- 31/03/23	31/03/23- 31/03/24
Composite Net (%)	6.5	70.2	-20.7	-11.9	-10.8
Benchmark (%)	-8.7	45.0	13.8	-4.7	24.5
CAD	31/03/19- 31/03/20	31/03/20- 31/03/21	31/03/21- 31/03/22	31/03/22- 31/03/23	31/03/23- 31/03/24
Composite Net (%)	10.8	61.0	-25.4	-6.8	-11.3
Benchmark (%)	-4.9	37.1	7.1	0.8	23.8
AUD	31/03/19- 31/03/20	31/03/20- 31/03/21	31/03/21- 31/03/22	31/03/22- 31/03/23	31/03/23- 31/03/24
Composite Net (%)	20.7	46.5	-23.9	-3.6	-9.0
Benchmark (%)	3.6	24.8	9.3	4.3	27.1


Benchmark is MSCI ACWI Index.

Source: Revolution, MSCI.


The Health Innovation composite is more concentrated than the MSCI ACWI Index.

Top Ten Largest Holdings

Stock Name	Description of Business	% of Portfolio
ShockWave Medical	Medical devices manufacturer	8.0
Moderna	Biotechnology developing mRNA-based therapeutics	6.9
Dexcom	Continuous glucose monitoring technology for diabetes management	5.9
argenx	Antibody based drug development	5.7
Genmab	Antibody based drug development	5.7
Edwards Lifesciences	Services to treat late-stage cardiovascular disease	5.3
Sartorius Group	Biopharmaceutical and laboratory equipment supplier	4.6
Ambu	Danish developer, producer and marketer of life saving equipment	4.5
ALK-Abello	Health care	4.4
Exact Sciences	Non-invasive molecular tests for early cancer detection	4.3
Total		55.3



Industry Weights	(%)
1 Biotechnology	41.7
2 Health Care Equipment & Supplies	30.6
3 Life Sciences Tools & Services	12.7
4 Health Care Technology	9.4
5 Pharmaceuticals	4.4
6 Cash	1.2



Regional Weights	(%)
1 North America	65.2
2 Europe (ex UK)	28.4
3 Developed Asia Pacific	2.4
4 Emerging Markets	1.9
5 UK	1.0
6 Cash	1.2

Figures may not sum due to rounding.

Voting Activity

Votes Cast in Favour		Votes Cast Against		Votes Abstained/Withheld	
Companies	3	Companies	1	Companies	None
Resolutions	35	Resolutions	1	Resolutions	None

Company Engagement

Engagement Type	Company
Environmental	Twist Bioscience Corporation
Governance	ALK-Abello A/S, Exscientia, Genmab A/S, Sartorius Aktiengesellschaft, WuXi Biologics (Cayman) Inc.

Company	Engagement Report
Exscientia	<p>Objective: Because of the recent upheaval within Exscientia's boardroom, as shareholders, it was imperative to assess the board's response to these challenges and evaluate their commitment to fostering better stewardship within the company.</p> <p>Discussion: After the CEO's dismissal due to misconduct and the chair's resignation, Exscientia is focusing on maintaining unity and transparency to rebuild trust internally and externally. The company is shifting from an ad-hoc approach to a more systematic and focused strategy for governance discipline. Exscientia's board has devised a stepwise plan for recovery, emphasising the implementation of best practices and soliciting input from all levels of the organisation. Regular town hall meetings/listening sessions were initiated to foster a culture of inclusivity and candour. A process to identify the new CEO is also underway. The board is open and straight about the fact that Exscientia now needs to continue focusing on science and accelerate its timeline when possible.</p> <p>Outcome: The recent actions of the board and its new priorities reflect Exscientia's efforts to navigate through the challenges, stabilise the company, and maintain shareholder confidence by promoting transparency, accountability and sound governance principles. It will be essential for Exscientia's board to continue demonstrating good stewardship in the face of adversity and seeing the company execute its strategy and grow.</p>
WuXi Biologics	<p>Objective: Unprecedented price volatility has affected WuXi Biologics' share price. Much of this is due to geopolitical tensions, but part of the volatility can be attributed to management communication. We spoke to CEO Chris Chen twice to understand his communication skills and how he managed this volatility.</p> <p>Discussion: WuXi Biologics had been anomalously bullish while the rest of the biotech industry struggled - having maintained their targets for the year and been persistently positive, they issued an unexpected profit warning in early December and noted that targets for adding new projects would be missed. In January, WuXi Biologics' optimism recovered - full-year project targets had been met (despite the warning), and guidance for 2024 project numbers was revised upwards. We were concerned by the lack of consistency of these messages - and why management appeared to have such limited visibility over company performance. Chris Chen accepted that guidance had not been perfect and the company should have communicated weakness earlier - he said that management was guilty of over-optimism - it had always set challenging goals and met them in the past. He also noted that a pick up in projects in December had been unexpected - and that there is a short lead time on early-stage projects, so they did not have visibility over the turnaround when the announcement was made.</p> <p>After this, WuXi Biologics has been a target of the US Biosecure Act, leading to substantial share price volatility. This appears to be being managed reasonably - the company has sensible strategies to deal with what will be a period marred by geopolitical tensions - it has held town halls to communicate with staff clearly and to try to improve morale - and is focusing on ensuring work continues as usual. It is hoped that a long-term focus on client satisfaction and project delivery will be more important than the current tensions in the US and China.</p> <p>Outcome: We were pleased that Chris Chen acknowledged the company's communication shortcomings and hope that a lesson has been learned. It is reassuring that WuXi Biologics are managing current volatility with a reassuringly long-term client-centric mindset.</p>

New Purchases

Stock Name	Transaction Rationale
BioNTech	We decided to take a position in BioNTech, a leading oncology-focused biotechnology company. We believe the combination of deep cancer expertise from the founders' decades of experience, its strong balance sheet of over \$16bn in cash, and its access to new technologies, through internal development and partnerships, materially increases the company's chance of success. The market's focus on its declining COVID-19 vaccine revenues has left its valuation depressed, undervaluing the breadth and depth of its drug pipeline. We took the opportunity to add it to the portfolio.
Inspire Medical Systems	Inspire offers a revolutionary way of addressing obstructive sleep apnoea (OSA). Its implant stimulates a nerve to push the tongue forward and clear the throat. It is used as an alternative to pressurised masks worn while sleeping, which can have low compliance rates. With only 50k devices implanted today and an estimated 6m severe OSA patients alone in the US, there is potential to grow the number of procedures at over 20% per year for the next 10 years. Inspire has made clear progress in unlocking this market by evidencing the implant's effectiveness, making the procedure easier, improving awareness and establishing reimbursement, and it is now working to unlock surgeon capacity to boost procedure numbers further. Its stock price has halved since June due to the perceived impact of the obesity drugs despite these having no effect in treating OSA due to tongue collapse, which Inspire's devices treat. This has provided an attractive entry point to take a position in the company.
Insulet	We took a new position in Insulet which has developed the only fully disposable and automated insulin delivery pump on the market. Its easy-to-use, compact tubeless pump connects to a continuous glucose monitoring device to administer insulin in a more efficient way than alternatives. This has led it to take share rapidly against competitors. We believe that Insulet can expand its share in type 1 diabetes patients, but its largest opportunity will be its increased adoption by the 2.8m insulin-intensive type 2 diabetes sufferers in the US where pumps are less than 5% penetrated. Our base case has the company growing its revenues at over 20% per year over the next five years, as well as expanding margins as it scales. Its stock price remains depressed due to fears that obesity drugs will limit its addressable market. This presented an attractive valuation opportunity to take an initial holding.
Twist Bioscience	Twist Bioscience manufactures DNA which is used in a number of applications such as in drug development, synthetic biology and clinical diagnostics. It makes synthetic DNA at a lower cost, at a higher throughput and with fewer errors than competitors. Its engineering-led approach can produce replicable success across various markets. Firstly, Twist has the potential to take share in the synthetic biology market through customer acquisition and new products and by the accelerated adoption of its sequencing products in the rapidly expanding diagnostics market. This can drive Twist's revenue growth higher, which combined with its recent capacity expansion, will lead to improved profitability over the next five years. Beyond this, the company also has compelling outlier potential in nascent markets such as in energy storage or its optimised antibodies for drug development.

Complete Sales

Stock Name	Transaction Rationale
Masimo	We sold the holding in Masimo, a developer of non-invasive patient monitoring devices. This was after already reducing the holding earlier in the month to fund a new purchase in Inspire Medical. Masimo's core business of monitoring infrastructure for hospitals is high quality, but its sales had slowed due to budget tightening across its customer base. More concerning was the severe hit in demand for its premium audio business which it acquired in 2022. We have monitored the progress of this acquisition since its completion and have concluded that it has worsened the quality of the business overall. We have therefore reallocated the proceeds of the sale to companies where we have more conviction.
Novocure	We decided to sell the position in Novocure. The company's Tumour Treating Field (TTF) devices emit electric fields which can stop and reverse the progression of cancer. After disappointing results in phase three trials in lung and ovarian cancer last year, we have less conviction that its TTF technology can become a backbone of cancer treatments in the future as the oncology field continues to change rapidly. With the next key trial results not expected for some time, we decided to reallocate the proceeds to a higher conviction new idea.
Teladoc	We sold the holding in Teladoc, the virtual healthcare company, due to its worsening growth prospects and a lack of faith in its management team. The pandemic propelled Teladoc to be the dominant telemedicine provider in the US and entrenched relationships with health insurers and employers. However, the company has not been able to leverage its platform across primary and chronic care to demonstrate value in the way we would have hoped. The cross-selling of its services has disappointed, and alongside slowing growth for its BetterHelp mental health app, undermined our confidence that the management team have the skills to navigate the complex needs of its customer base in the face of increasing competition.

MSCI Source: MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.